Astera Labs, Inc. $ALAB Shares Sold by Greenhouse Funds LLLP

Greenhouse Funds LLLP lowered its position in Astera Labs, Inc. (NASDAQ:ALAB) by 39.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 321,475 shares of the company’s stock after selling 213,060 shares during the period. Astera Labs comprises approximately 2.3% of Greenhouse Funds LLLP’s holdings, making the stock its 23rd largest position. Greenhouse Funds LLLP owned about 0.19% of Astera Labs worth $62,945,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Assetmark Inc. raised its stake in shares of Astera Labs by 374.1% during the 3rd quarter. Assetmark Inc. now owns 128 shares of the company’s stock worth $25,000 after buying an additional 101 shares in the last quarter. Clearstead Trust LLC grew its holdings in Astera Labs by 46,100.0% during the second quarter. Clearstead Trust LLC now owns 462 shares of the company’s stock worth $42,000 after acquiring an additional 461 shares during the period. Advisors Asset Management Inc. raised its position in Astera Labs by 68.6% in the second quarter. Advisors Asset Management Inc. now owns 477 shares of the company’s stock worth $43,000 after acquiring an additional 194 shares in the last quarter. Manchester Capital Management LLC raised its position in Astera Labs by 141.5% in the second quarter. Manchester Capital Management LLC now owns 483 shares of the company’s stock worth $44,000 after acquiring an additional 283 shares in the last quarter. Finally, Pinpoint Asset Management Singapore Pte. Ltd. acquired a new stake in Astera Labs in the third quarter valued at $47,000. Hedge funds and other institutional investors own 60.47% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the stock. Weiss Ratings cut shares of Astera Labs from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, February 23rd. Loop Capital began coverage on shares of Astera Labs in a report on Thursday, March 5th. They set a “buy” rating and a $250.00 price objective on the stock. Barclays set a $165.00 price target on shares of Astera Labs in a research report on Thursday, January 15th. Citigroup dropped their price objective on Astera Labs from $275.00 to $250.00 and set a “buy” rating for the company in a research note on Wednesday, February 11th. Finally, Royal Bank Of Canada started coverage on Astera Labs in a report on Wednesday, January 14th. They issued an “outperform” rating and a $225.00 target price on the stock. Fifteen equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Astera Labs presently has a consensus rating of “Moderate Buy” and a consensus price target of $195.89.

Astera Labs Price Performance

ALAB stock opened at $124.71 on Thursday. The company’s 50 day simple moving average is $150.00 and its 200-day simple moving average is $168.89. Astera Labs, Inc. has a 12 month low of $47.13 and a 12 month high of $262.90. The firm has a market capitalization of $21.23 billion, a PE ratio of 102.22, a P/E/G ratio of 2.29 and a beta of 1.74.

Astera Labs (NASDAQ:ALAB) last announced its earnings results on Tuesday, February 10th. The company reported $0.58 EPS for the quarter, beating analysts’ consensus estimates of $0.51 by $0.07. Astera Labs had a return on equity of 16.12% and a net margin of 25.70%.The firm had revenue of $270.58 million for the quarter, compared to analysts’ expectations of $249.46 million. During the same quarter in the prior year, the firm earned $0.37 EPS. Astera Labs’s quarterly revenue was up 91.8% on a year-over-year basis. Astera Labs has set its Q1 2026 guidance at 0.530-0.540 EPS. As a group, sell-side analysts anticipate that Astera Labs, Inc. will post 0.34 earnings per share for the current year.

Insider Activity

In other Astera Labs news, CFO Michael Truett Tate sold 12,001 shares of the company’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $123.81, for a total value of $1,485,843.81. Following the transaction, the chief financial officer directly owned 192,083 shares in the company, valued at approximately $23,781,796.23. This represents a 5.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Jitendra Mohan sold 94,971 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $123.81, for a total transaction of $11,758,359.51. Following the sale, the chief executive officer directly owned 1,452,739 shares in the company, valued at $179,863,615.59. This represents a 6.14% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 224,292 shares of company stock worth $27,676,069 in the last quarter. Corporate insiders own 12.50% of the company’s stock.

Astera Labs Profile

Astera Labs is a fabless semiconductor company that develops connectivity solutions for data center and cloud infrastructure. The firm focuses on addressing signal integrity and link management challenges that arise as server architectures incorporate higher-bandwidth processors and accelerators. Its technology is aimed at improving reliability and performance for high-speed interconnects used in servers, storage systems and compute accelerators.

The company’s product portfolio centers on silicon devices and accompanying firmware and software that enhance and manage high-speed links.